Vor Biopharma (VOR) EBITDA (2020 - 2026)

Vor Biopharma (VOR) has 7 years of EBITDA data on file, last reported at -$220.3 million in Q1 2026.

• Quarterly EBITDA fell 578.26% year-over-year to -$220.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$883.8 million (down 645.92% YoY) and the FY2025 annual result came in at -$696.0 million, down 495.78% from the prior year.
• EBITDA fell to -$220.3 million in Q1 2026 per VOR's latest filing, from $1.7 billion in the prior quarter.
• Across five years, EBITDA topped out at $1.7 billion in Q4 2025 and bottomed at -$1.6 billion in Q2 2025.
• The 5-year median for EBITDA is -$27.8 million (2023), against an average of -$73.1 million.
• Peak annual rise in EBITDA reached 5701.43% in 2025, while the deepest fall reached 5556.24% in 2025.
• Tracing VOR's EBITDA over 5 years: stood at -$23.5 million in 2022, then slipped by 10.88% to -$26.1 million in 2023, then slipped by 18.04% to -$30.8 million in 2024, then jumped by 5701.43% to $1.7 billion in 2025, then plunged by 112.79% to -$220.3 million in 2026.
• Per Business Quant, the three latest VOR EBITDA figures stand at -$220.3 million (Q1 2026), $1.7 billion (Q4 2025), and -$812.7 million (Q3 2025).

Peer Comparison